Vaginal Pessary Market is estimated to be valued at USD 430.8 Mn in 2025 and is expected to reach USD 839.5 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 10.0% from 2025 to 2032.
The market for vaginal pessaries is seeing consistent growth that is fueled by a growing incidence of pelvic organ prolapse (POP) and urinary incontinence among females, especially among the geriatric population. Growing awareness regarding conditions affecting women, particularly those that involve the pelvic floor disorders, is causing women to increasingly consider conservative treatment approaches such as the use of vaginal pessaries.
For instance, in 2025, India launched the National Women's Health Program, which involves the dispensing of vaginal pessaries in rural and underprivileged regions. The program is centered on offering cost-effective and accessible healthcare solutions to women, treating conditions such as POP and urinary incontinence in a non-surgical manner.
These devices are commonly utilized as non-surgical measures for POP and urinary incontinence and are a cost-effective and reversible option relative to surgical treatment. Advances in materials and the use of custom-fit pessaries are enhancing patient comfort and performance, further increasing market growth. Yet, difficulties like low levels of awareness and cultural stigma attached to the use of vaginal devices in some areas may hinder the growth of the market. Regulatory challenges involving product approval and quality control are also a challenge.
|
Current Events |
Description and its impact |
|
Advancements in Vaginal Pessary Design |
|
|
Increased Awareness and Education |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Reimbursement for vaginal pessaries involves specific coding and billing considerations under Medicare. Pessaries are considered both a supply and an orthotic and should be coded using HCPCS codes A4561 (rubber pessary) or A4562 (non-rubber, typically silicone). A4562 is more commonly used due to its lower risk of allergic reactions and higher reimbursement—approximately $44, compared to $17 for A4561. However, the reimbursement still falls below the market cost, leading many OB-GYN practices to issue prescriptions for patients to purchase the pessary from a supplier directly, rather than stocking and billing for the device themselves. In such cases, either the patient or supplier can bill Medicare, but a prescription is required.
If the practice chooses to provide the device, they may bill the patient directly, keeping in mind Medicare’s limited charge rules for non-participating providers. For insertion, use CPT code 57160, which has a zero-day global period under Medicare. When pessary care is provided during an annual exam, modifier -25 should be added to the E/M code. Follow-up cleanings or reinsertions should be billed with the appropriate E/M code. Diagnosis coding should reference ICD-9 codes from the 618.x series, depending on the type and degree of prolapse.
The ring pessary category captured the greatest share of the market, which was 37.2%, a commanding percentage fuelled by a number of factors. Among the main reasons for its usage is that it is very convenient to insert and withdraw. This renders it very convenient for both patients and clinicians since it makes relatively simple management and upkeep possible. Ease of use has led to high uptake among patients, particularly those requiring non-surgical treatment for conditions such as pelvic organ prolapse.
To learn more about this report, Download Free Sample
In 2025, North America held a significant share in the global vaginal pessary market. The region's market growth is due to factors such as the presence of advanced healthcare infrastructure, high awareness about pelvic organ prolapses and stress urinary incontinence, and the availability of technologically advanced medical devices. A large geriatric population and increasing demand for non-invasive treatment options contribute to the market growth in this region.
Europe is another prominent market for vaginal pessaries. The region's market growth is driven by factors such as a high prevalence of pelvic organ prolapses and stress urinary incontinence among women, increasing healthcare expenditure, and favorable reimbursement policies. The presence of key market players and ongoing research and development (R&D) activities further contribute to the market growth in Europe.
The vaginal pessary market in Asia Pacific is expected to witness significant growth during the forecast period. This growth is due to factors such as a large population base, increasing awareness about pelvic floor disorders, and rising healthcare expenditure. Moreover, the growing adoption of advanced medical technologies and the expansion of healthcare infrastructure in countries like China and India are likely to fuel market growth in this region.
The United States leads the vaginal pessary market with a considerable share based on its developed healthcare infrastructure and high rates of awareness about pelvic health. As its population continues to age and demand for non-surgical treatments rises, the U.S. has been the largest market for vaginal pessaries. Hospitals and medical facilities in the country provide extensive pessary services, fuelling adoption even more. The U.S. market also has the advantage of robust regulatory systems that guarantee the efficacy and safety of these devices.
Germany is Europe's top market for vaginal pessaries, underpinned by its established healthcare system and high level of acceptance for non-surgical procedures. The population aging and increasing incidence of pelvic organ prolapse (POP) in the country have driven demand for vaginal pessaries. Germany's strong medical device regulatory environment has also promoted the supply of high-quality pessary products.
China is witnessing strong growth in the vaginal pessary market, led by rising awareness of women's health concerns and enhancing access to healthcare. With one of the largest populations in the world, demand for pelvic health products is increasing, especially in urban regions. China's growing healthcare infrastructure and initiatives by the government to enhance women's health services are anticipated to drive market growth in the next few years.
India is set to emerge as a strong contributor to the market for vaginal pessaries in the Asia Pacific region. The country boasts a large population, and as there is a rise in awareness regarding healthcare, the demand for inexpensive, minimally invasive care in the form of vaginal pessaries is escalating. With a growing population, as women increasingly learn about pelvic floor disorders and turn towards treatment, India should witness major market growth, driven by innovations in digital healthcare delivery and access to medical devices.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 430.8 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 10.0% | 2032 Value Projection: | USD 839.5 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Cooper Companies, Inc., MedGyn Products, Inc., Milex Products, Inc., Personal Medical Corp., Panpac Medical Corp., Gyneas, Integra LifeSciences, Boston Scientific Corporation, Coloplast Corp, Bray Group Limited, Marina Medical Instruments, Bioteque America Inc., Sugar International, and for.me.sa. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Growing prevalence of pelvic organ prolapses and stress urinary incontinence among women is a significant driver for the vaginal pessary market. These conditions affect a large number of women worldwide, thus creating a demand for effective treatment options such as vaginal pessaries. For instance, in April 2022, according to article published in UpToDate, an electronic clinical resource tool between 15%-80% of women with pelvic floor dysfunction also have stress urinary incontinence (SUI) and pelvic organ prolapse (POP).
In 2024, BMC Women's Health study evaluated the incidence of SUI symptoms in Palestinian women. The study found that 26.9% of the participants had SUI symptoms, with urinary leakage during activities such as coughing, sneezing, and laughing being frequent events.
Increasing awareness about pelvic floor disorders and the availability of treatment options such as vaginal pessaries are driving the market growth of the global vaginal pessary market. Educational campaigns, initiatives by healthcare organizations, and awareness programs contribute in improving understanding and recognition of these conditions, thus leading to increased demand for treatment options.
The global increase in the geriatric population, who are more prone to pelvic organ prolapse, contributes to the growth of the global vaginal pessary market. As the elderly population continues to grow, the demand for treatment options to manage pelvic floor disorders is expected to rise thus the driving market growth.
There is a growing preference for non-invasive treatment options among patients. Vaginal pessaries provide a non-invasive approach to manage pelvic organ prolapse and stress urinary incontinence, thereby avoiding the need for surgery. The demand for non-invasive treatments is increasing, which positively impacts the market growth of vaginal pessaries.
Growing government initiatives are a major opportunity for the vaginal pessaries market. Governments from different regions are making proactive efforts to enhance women's health and are investing in healthcare infrastructure, including the delivery of advanced medical devices like vaginal pessaries. In 2024, the Centers for Medicare & Medicaid Services in the U.S. added coverage for vaginal pessaries as a reimbursable treatment option for pelvic organ prolapse and urinary incontinence. It has enhanced non-surgical treatments' accessibility for millions of women, especially to the elderly.
Ongoing research and development in vaginal pessaries offer the possibility of technological innovation. Design innovation, new materials, and process innovation can drive the creation of more comfortable, efficient, and patient-friendly pessaries. Technologies like adjustable pessaries or sensor-enabled pessaries for real-time monitoring can provide new opportunities and market spaces.
Share
Share
About Author
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
